United Therapeutics to acquire competitor pharmaceutical company

United Therapeutics Corp. has reached a deal to acquire California-based SteadyMed Therapeutics Inc. in a deal valued at $216 million, a move that eliminates a competitive threat to the Maryland biotech by pulling it into its own corner. The Silver Spring drugmaker will acquire SteadyMed for $4.46 per share in cash at closing, plus an additional $2.63 per share in cash when the company reaches a milestone related to the commercialization of Trevyent, a development-stage drug-device combination product…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news